Gyre Therapeutics Inc.

NASDAQ: GYRE · Real-Time Price · USD
8.04
-0.18 (-2.19%)
At close: Aug 15, 2025, 2:34 PM

Gyre Therapeutics Income Statement

Financials in USD. Fiscal year is undefined.
Fiscal Year FY 2024 FY 2023 FY 2022 FY 2021
Period Ending Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021
Revenue
105.76M 113.45M 102.29M 7.34M
Cost of Revenue
3.88M 4.64M 798K 7.38M
Gross Profit
101.87M 108.81M 97.5M -42K
Operating Income
16.16M -67.23M 9.2M -87.89M
Interest Income
1.55M 1.04M 726K 39K
Pretax Income
23.22M -76.97M 9.41M -87.93M
Net Income
12.09M -92.93M 2.3M -87.93M
Selling & General & Admin
73.62M 75.82M 71.61M 18.82M
Research & Development
12.02M 13.78M 16.69M 68.89M
Other Expenses
66K 86.44M n/a 143K
Operating Expenses
85.71M 176.04M 88.29M 87.85M
Interest Expense
n/a n/a n/a n/a
Selling & Marketing Expenses
57.51M 61.16M 54.24M n/a
Cost & Expenses
89.59M 180.68M 93.09M 95.23M
Income Tax Expense
5.32M 8.52M 5.1M -39K
Shares Outstanding (Basic)
85.09M 65.83M 76.74M 30.64M
Shares Outstanding (Diluted)
102.29M 65.83M 75.69M 30.64M
EPS (Basic)
0.14 -1.41 0.03 -2.87
EPS (Diluted)
0.05 -1.41 0.03 -2.87
EBITDA
17.82M 20.33M 10.33M -87.6M
EBIT
16.23M 19.21M 9.2M -87.93M
Depreciation & Amortization
1.59M 1.11M 1.13M 290K